$SPRC

Shrem Itschak sold $5K of SPRC

Shrem Itschak sold 462 shares of SciSparc Ltd. (SPRC) at $10.00 on 2026-06-01.

Original reporting
SEC EDGAR · Shrem Itschak
Published Jun 3, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 12:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SPRC
Neutral
medium confidence
Mentioned
$SPRC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SPRCNeutralLow
01

Why it matters

Traders may monitor for clustering of insider sales/buys or larger transactions, but this specific print is unlikely to drive a major repricing by itself.

02

Market read

A small insider sale disclosed today may slightly affect near-term sentiment, but it lacks a fundamental catalyst.

03

What to watch

No 10b5-1 plan is noted, but the filing alone doesn’t reveal intent, tax considerations, or whether other insiders are buying/selling around the same period.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed today (2026-06-03) covering a sale on 2026-06-01

Background

This is an SEC Form 4 insider transaction disclosure (director open-market sale).

Company-level read

Ticker impact

$SPRCNeutralMedium confidence
Context

SciSparc director Shrem Itschak sold 462 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Low likelihood of a sustained price move solely from this Form 4.

Evidence & confidence

The filing is a routine insider transaction with modest proceeds ($4,620) and no stated fundamental catalyst; such prints typically have limited immediate market impact unless part of a larger pattern.

Market effects

No clear sector read-through from a single small insider sale.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio rebalancing rather than a bearish view, especially given the small size.

Key entities

  • SciSparc Ltd.

    Subject of the SEC Form 4 insider transaction; director sold 462 shares at $10.00 on 2026-06-01.

  • Shrem Itschak

    Director who executed the open-market sale disclosed in the filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SPRCMedAI 8/10

SPRC Stock Jumps As SciSparc Advances Tourette Trial And AI Pivot

SciSparc Ltd. (SPRC) stock surged 39.44% on October 26, 2026, driven by positive sentiment around its Tourette syndrome drug trial and AI initiatives. The company's subsidiary, NeuroThera Labs, advanced its drug candidate SCI-110 into a Phase IIb trial, while its AI division, CliniQuantum, demonstrated significant performance improvements. SPRC trades at a fraction of its book value, reflecting both skepticism and potential value if its pipeline or AI initiatives gain traction.

$SPRCMedAI 8/10

Yale is one of three centers ready to receive a Tourette’s trial drug

SciSparc (Nasdaq: SPRC) announced that its subsidiary, NeuroThera Labs (TSXV: NTLX), has completed manufacturing and obtained regulatory approval for its Phase IIb clinical trial of SCI-110, a drug for Tourette Syndrome. The trial will be conducted at three sites, including Yale and Tel Aviv Sourasky Medical Center. SCI-110 combines dronabinol and PEA, aiming to address unmet treatment needs for TS. Patient enrollment is expected to begin soon, marking a significant milestone for NeuroThera.

$SPRCMed

Why is Scisparc stock surging today?

Scisparc (SPRC) stock rose 37% in pre-market trading after announcing a strategic shift to AI-powered technologies, focusing on cybersecurity and fintech. The Tel Aviv-based firm, previously a clinical-stage pharmaceutical developer, plans to explore agentic AI opportunities but cautioned no guarantees. The surge contrasts with broader tech selloffs due to inflation fears. No analyst upgrades accompanied the news, with recent ratings being 'hold' and 'sell'.

$SPRCHighAI 8/10

Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.